Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 6, 2014, Pages

  Zhang, Ling ^a   Zeng, Xiaoxi ^a   Fu, Ping ^a   Wu, Hong Mei ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; POTASSIUM; RAMIPRIL;

ALL CAUSE MORTALITY; ANURIA; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CLINICAL EVALUATION; COUGHING; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; END STAGE RENAL DISEASE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HUMAN; HYPERKALEMIA; KIDNEY FUNCTION; KIDNEY PRESERVATION; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PERITONITIS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; DISEASE COURSE; DRUG EFFECTS; KIDNEY; KIDNEY FAILURE, CHRONIC; META ANALYSIS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84942145115     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009120.pub2     Document Type: Review

References (56)

1. Li PK, Chow K, Wong TY, Leung C, Szeto CC. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Annals of Internal Medicine 2003;139(2):105-12. [MEDLINE: 12859160]
2. Li PK, Chow K, Wong TY, Leung C, Szeto CC. Preservation of residual renal function in peritoneal dialysis patients by angiotensin-converting-enzyme inhibitor -a prospective study [abstract no: F-FC004]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):1a. [CENTRAL: CN-00446373]
3. Phakdeekitcharoen B, Leelasa-nguan P. Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients. American Journal of Kidney Diseases 2004;44(4):738-46. [MEDLINE: 15384026]
4. Reyes-Marin FA, Calzada C, Ballesteros A, Amato D. Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study. Revista de Investigacion Clinica 2012;64(4):315-21. [MEDLINE: 23227581]
5. Suzuki H, Kanno Y, Sugahara S. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. American Journal of Kidney Diseases 2004;43(6):1056-64. [MEDLINE: 15168386]
6. Wang J, Xiao MY. Protective effects of valsartan on residual renal function in patients on CAPD. Chinese Journal of Blood Purification 2005;4(11):605-6.
7. Zhong H, Sha CH, Sui TL, Qiu HY, Liu F, Qin W, et al.Effects of irbesartan on residual renal function in peritoneal dialysis patients. Chinese Journal of Nephrology 2007;23(7):413-6.
8. Cioni A, Sordini C, Cavallini I, Bigazzi R, Vito M, Campese VM. Angiotensin receptor blocker telmisartan improves insulin sensitivity in peritoneal dialysis patients. Peritoneal Dialysis International 2010;30(1):66-71. [MEDLINE: 20056982]
9. Favazza A, Motanaro D, Messa P, Antonucci F, Gropuzzo M, Mioni G. Peritoneal clearances in hypertensive CAPD patients after oral administration of clonidine, enalapril, and nifedipine. Peritoneal Dialysis International 1992;12(3):287-91. [MEDLINE: 1511045]
10. Huang YH. Effect of angiotensin-converting enzyme inhibitors on serum levels of erythropoietin in patients on peritoneal dialysis. Di Yi Junyi Daxue Xuebao 2002;22(1):74-5. [MEDLINE: 12390854]
11. Kolesnyk I, Noordzij M, Dekker FW, Boeschoten EW, Krediet RT. Treatment with angiotensin II inhibitors and residual renal function in peritoneal dialysis patients. Peritoneal Dialysis International 2011;31(1):53-9. [MEDLINE: 20522672]
12. Nakamoto H, Kanno Y, Okada H, Suzuki H. Erythropoietin resistance in patients on continuous ambulatory peritoneal dialysis. Advances in Peritoneal Dialysis 2004;20:111-6. [MEDLINE: 15384808]
13. Collins JF, Robson R, MacMahon S, Bailey RR, PERFECT Study Group. Safety and efficacy of enalapril and simvastatin in dialysis patients [abstract]. 6th Asian Pacific Congress of Nephrology; 1995 Dec 5-9; Hong Kong. 1995:144. [CENTRAL: CN-00460572]
14. Robson R, Collins J, Johnson R, Kitching R, Searle M, Walker R, et al.Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis. The Perfect Study Collaborative Group. Journal of Nephrology 1997;10(1):33-40. [MEDLINE: 9241623]
15. Robson R, Collins J, Kitchings R, Searle M, Walker R, Sharpe N, et al.A randomized controlled trial of simvastatin and enalapril in dialysis patients: effects on serum lipoproteins and left ventricular mass [abstract]. Journal of the American Society of Nephrology 1994;5(3):526. [CENTRAL: CN-00550525]
16. Robson RA, Collins J, Walker RJ, MacMahon S. A randomised controlled trial of simvastatin and enalapril in dialysis patients: effects on serum lipoproteins and left ventricular mass [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:530. [CENTRAL: CN-00509440]
17. Walker RJ, Sutherland WH, Walker H. Simvastatin and cholesteryl ester transfer (CET) activity in renal failure (RF) [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:529. [CENTRAL: CN-00509553]
18. Walker RJ, Sutherland WH, Walker H, Robson RA, MacMahon SA. The effects of simvastatin and enalapril on plasma cholesteryl ester transfer (CET) activity in renal failure (RF) [abstract]. 6th Asian Pacific Congress of Nephrology; 1995 Dec 5-9; Hong Kong. 1995:28. [CENTRAL: CN-00461958]
19. Walker RJ, Sutherland WH, Walker HL, MacMahon S, Robson RA. Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. PERFECT Study Collaborative Group. Nephrology Dialysis Transplantation 1997;12(1):87-92. [MEDLINE: 9027779]
20. Rojas-Campos E, Cortes-Sanabria L, Martinez-Ramirez HR, Gonzalez L, Martin-del-Campo F, Gonzalez-Ortiz M, et al.Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. Peritoneal Dialysis International 2005;25(6):576-82. [MEDLINE: 16411525]
21. Rojas-Campos E, Martinez-Ramirez H, Cortes-Sanabria L, Camacho R, Martin-del-Campo F, Cueto-Manzano AM. Oral verapamil increases ultrafiltration and peritoneal small solute clearance of CAPD patients [abstract no: SA-FC130]. Journal of the American Society of Nephrology 2005;16:110A. [CENTRAL: CN-00583927]
22. Shigenaga A, Tamura K, Dejima T, Ozawa M, Wakui H, Masuda S, et al.Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis. Nephron Clinical Practice 2009;112(1):c31-c40. [MEDLINE: 19342867]
23. Suzuki H, Nakamoto H, Okada H, Sugahara S, Kanno Y. A selective angiotensin receptor antagonist, valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness. Advances in Peritoneal Dialysis 2003;19:59-66. [MEDLINE: 14763035]
24. Medcalf JF, Carr S, Walls J, Harris KP. The effect of ACE Inhibitors and AII receptor antagonists on erythrocytosis in patients on CAPD taking EPO [abstract]. 37th Congress. European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17-20; Nice, France. 2000:235. [CENTRAL: CN-00461288]
25. NCT00721773. Effects of benazepril, valsartan or combination of both on residual renal function in peritoneal dialysis patients. http://clinicaltrials.gov/ct2/show/NCT00721773 (accessed 12 June 2014).
26. NCT01041963. The effect of enalapril and losartan on peritoneal membrane in continuous ambulatory peritoneal dialysis patients. http://clinicaltrials.gov/ct2/show/NCT01041963 (accessed 12 June 2014).
27. Akbari A, Knoll G, Ferguson D, McCormick B, Davis A, Biyani M. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peritoneal dialysis: systematic review and meta-analysis of randomized controlled trials. Peritoneal Dialysis International 2009;29(5):554-61. [MEDLINE: 19776050]
28. Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. Journal of the American Society of Nephrology 2001;12(10):2158-62. [MEDLINE: 11562415]
29. Blake PG. Integrated end-stage renal disease care: the role of peritoneal dialysis. Nephrology Dialysis Transplantation 2001;16 Suppl 5:61-6. [MEDLINE: 11509687]
30. Cancarini G, Bunori G, Camererini C, Brasa S, Manili L, Maiorca R. Renal function recovery and maintenance of residual diuresis in CAPD and hemodialysis. Peritoneal Dialysis Bulletin 1986;6(2):77-9. [EMBASE: 1986213696]
31. Cueto-Manzano AM. Peritoneal dialysis in Mexico. Kidney International 2003;83(Suppl):S90-2. [MEDLINE: 12864882]
32. Fang W, Oreopoulos DG, Bargman JM. Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis. Nephrology Dialysis Transplantation 2008;23(11):3704-10. [MEDLINE: 18567695]
33. Fenton SS, Schaubel DE, Desmeules M, Morrison HI, Mao Y, Copleston P, et al.Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. American Journal of Kidney Diseases 1997;30(3):334-42. [MEDLINE: 9292560]
34. Gokal R, Figueras M, Olle A, Rovira J, Badia X. Outcomes in peritoneal dialysis and haemodialysis-a comparative assessment of survival and quality of life. Nephrology Dialysis Transplantation 1999;14 Suppl 6:24-30. [MEDLINE: 10528709]
35. Heaf JG, Lokkegaard H, Madsen M. Initial survival advantage of peritoneal dialysis relative to haemodialysis. Nephrology Dialysis Transplantation 2002;17(1):112-7. [MEDLINE: 11773473]
36. Herget-Rosenthal S, von Ostrowski M, Kribben A. Definition and risk factors of rapidly declining residual renal function in peritoneal dialysis: an observational study. Kidney & Blood Pressure Research 2012;35(4):233-41. [MEDLINE: 22223267]
37. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120]
38. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
39. Kolesnyk I, Dekker FW, Noordzij M, le Cessie S, Struijk DG, Krediet RT. Impact of ACE inhibitors and AII receptor blockers on peritoneal membrane transport characteristics in long-term peritoneal dialysis patients. Peritoneal Dialysis International 2007;27(4):446-53. [MEDLINE: 17602154]
40. Li PK, Szeto CC, Law MC, Chau KF, Fung KS, Leung CB, et al.Comparison of double-bag and Y-set disconnect systems in continuous ambulatory peritoneal dialysis: a randomized prospective multicenter study. American Journal of Kidney Diseases 1999;33(3):535-40. [MEDLINE: 10070918]
41. Li PK, Szeto CC. Adequacy targets of peritoneal dialysis in the Asian population. Peritoneal Dialysis International 2001;21 Suppl 3:S378-83. [MEDLINE: 11887861]
42. Li LP, Chow KM. The cost barrier to peritoneal dialysis in the developing world-an Asian perspective. Peritoneal Dialysis International 2001;2001(21 Suppl 3):S307-13. [MEDLINE: 11887842]
43. Maiorca R, Brunori G, Zubani R, Cancarini GC, Manili L, Camerini C, et al.Predictive value of dialysis adequacy and nutritional indices for mortality and morbidity in CAPD and HD patients. A longitudinal study. Nephrology Dialysis Transplantation 1995;10(12):2295-305. [MEDLINE: 8808229]
44. Moist LM, Port FK, Orzol SM, Young EW, Ostbye T, Wolfe RA, et al.Predictors of loss of residual renal function among new dialysis patients. Journal of the American Society of Nephrology 2000;11(3):556-64. [MEDLINE: 10703680]
45. Patel N, Hu SL. Preserving residual renal function in dialysis: What we know. Seminars in Dialysis 2014;9(18):epub. [DOI: 10.1111/sdi.12302]
46. Schaubel DE, Fenton SS. Trends in mortality on peritoneal dialysis: Canada. Journal of the American Society of Nephrology 2000;11(1):126-33. [MEDLINE: 10616848]
47. Shafi T, Jaar BG, Plantinga LC, Fink NE, Sadler JH, Parekh RS, et al.Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. American Journal of Kidney Diseases 2010;56(2):348-58. [MEDLINE: 20605303]
48. Shemin D, Bostom AG, Lambert C, Hill C, Kitsen J, Kliger AS. Residual renal function in a large cohort of peritoneal dialysis patients: change over time, impact on mortality and nutrition. Peritoneal Dialysis International 2000;20(4):439-44. [MEDLINE: 11007376]
49. Suzuki H, Nakamoto H, Okada H, Sugahara S, Kanno Y. A selective angiotensin receptor antagonist, Valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness. Advances in Peritoneal Dialysis 2003;19:59-66. [MEDLINE: 14763035]
50. Suzuki T, Kanno Y, Nakamoto N, Okada H, Sugahara S, Suzuki H. Peritoneal dialysis versus hemodialysis: A five-year comparison of survival and effects on the cardiovascular system, erythropoiesis, and calcium metabolism. Advances in Peritoneal Dialysis 2003;19:148-54. [MEDLINE: 14763052]
51. Szeto CC, Wong TY, Leung CB, Wang AY, Law MC, Lui SF, et al.Importance of dialysis adequacy in mortality and morbidity of Chinese CAPD patients. Kidney International 2000;58(1):400-7. [MEDLINE: 10886588]
52. Termorshuizen F, Korevaar JC, Dekker FW, Van Manen JG, Boeschoten EW, Krediet RT. Hemodialysis and peritoneal dialysis: comparison of adjusted mortality rates according to the duration of dialysis: analysis of The Netherlands Cooperative Study on the Adequacy of Dialysis. Journal of the American Society of Nephrology 2003;14(11):2851-60. [MEDLINE: 14569095]
53. US Renal Data System. USRDS 2003 annual report: atlas of end-stage renal disease in the United States. Bethesda, MD, 2003. http://www.usrds.org/atlas03.aspx (accessed 12 June 2014):78-80.
54. Venkataraman V, Nolph KD. Preservation of residual renal function-an important goal. Peritoneal Dialysis International 2000;20(4):392-5. [MEDLINE: 11007370]
55. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al.Morphologic changes in the peritoneal membrane of patients with renal disease. Journal of the American Society of Nephrology 2002;13(2):470-9. [MEDLINE: 11805177]
56. Zhang L, Zeng X, Fu P, Wu HM. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for preserving residual kidney function in peritoneal dialysis patients. Cochrane Database of Systematic Reviews 2011, Issue 5. [DOI: 10.1002/14651858.CD009120]